Incidence of Orthostatic Hypotension in Schizophrenic Patients Using Antipsychotics at Sambang Lihum Mental Health Hospital, South Kalimantan
Article Sidebar
-
Psychosis disorder, Postural hypotension, Antipsychotic
Abstract
Schizophrenia is a psychiatric disorder that requires antipsychotics therapy. Antipsychotics cause many side effects, including orthostatic hypotension. The study aimed to describe the incidence of orthostatic hypotensive side effects experiences by schizophrenia patients at the Sambang Lihum Mental Health Hospital, South Kalimantan. This research was observational description research with data sampling by medical records. This research was conducted to 300 medical records of patients period January-December 2018 which received antipsychotics medication and data analyzed by univariate analysis. The results showed the number of patients who experienced orthostatic hypotension was 98 patients (32.67%) and no experienced were 202 patients (67.33%). Incidence of orthostatic hypotension in haloperidol 54.35% (N=46); trifluoperazine 100% (N=1); clozapine 84.62% (N=13); olanzapine 100% (N=1); haloperidol-chlorpromazine 27.27% (N=11); haloperidol-haloperidol 42.86% (N=7); clozapine-risperidone 16.67% (N=6); haloperidol-clozapine 15.05% (N=93); haloperidol-olanzapine 50% (N=2); haloperidol-risperidone 31.82% (N=22); trifluoperazine-olanzapine 100% (N=1); trifluoperazine-clozapine 22.22% (N=9); trifluoperazine-risperidone 5.56% (N=18); chlorpromazine-haloperidol-haloperidol 33.3% (N=3); chlorpromazine-haloperidol-trifluoperazine 100% (N=3); haloperidol-trifluoperazine-chlorpromazine 100% (N=1); chlorpromazine-haloperidol-clozapine 42.86% (N=7); chlorpromazine-trifluoperazine-clozapine 100% (N=1); chlorpromazine-trifluoperazine-olanzapine 100% (N=1); chlorpromazine-trifluoperazine-risperidone 50% (N=2); trifluoperazine-haloperidol-risperidone 100% (N=4); haloperidol-trifluoperazine-risperidone 100% (N=1); trifluoperazine-haloperidol-clozapine 40% (N=5); haloperidol-haloperidol-clozapine 80% (N=5); clozapine-risperidone-trifluoperazine 100% (N=4); risperidone-clozapine-haloperidol 20% (N=10). The conclusion from this study was the percentage of orthostatic hypotension on schizophrenia patients at the Sambang Lihum Mental Health Hospital was 32.67% (N=98).
Full text article
References
2. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195-203. doi:10.1093/schbul/sby058
3. Ministry of Health Republic of Indonesia. Hasil Utama Riskesdas 2018. Jakarta: Health Research and Development Agency, Ministry of Health Republic of Indonesia; 2018.
4. Rahman T, Lauriello J. Schizophrenia: An Overview. Focus (Am Psychiatr Publ). 2016;14(3):300-7. doi:10.1176/appi.focus.20160006
5. Stępnicki P, Kondej M, Kaczor AA. Current Concepts and Treatments of Schizophrenia. Molecules. 2018;23(8):2087. doi:10.3390/molecules23082087
6. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-56. doi:10.1002/wps.20567
7. Ferinauli F, Narulita S, Hijriyati Y. Effect of antipsychotic drugs and orthostatic hypotension on the risk of falling in schizophrenic patients. J Public Health Res. 2021;19(2):2184. doi:10.4081/jphr.2021.2184
8. Arnold AC, Shibao C. Current Concepts in Orthostatic Hypotension Management. Curr Hypertens Rep. 2013;15(4):304-12. doi:10.1007/s11906-013-0362-3
9. Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210-23. doi:10.2174/1570159X15666170630163616
10. Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. Drugs Aging. 2020;37(10):725-38. doi:10.1007/s40266-020-00796-5
11. Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163-91.
12. Yulianty MD, Cahaya N, Srikartika VM. Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. JSFK (Jurnal Sains Farmasi & Klinis). 2017;3(2):153-64. doi:10.29208/jsfk.2017.3.2.108
13. Patton GC, Sawyer SM, Santelli JS, Ross DA, Afifi R, Allen NB, et al. Our future: a Lancet commission on adolescent health and wellbeing. Lancet. 2016;387(10036):2423-78. doi:10.1016/S0140-6736(16)00579-1
14. Williams DR. Stress and the Mental Health of Populations of Color: Advancing Our Understanding of Race-related Stressors. J Health Soc Behav. 2018;59(4):466-85. doi:10.1177/0022146518814251
15. Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? J Transl Neurosci. 2016;1(1):37-42
16. Ran MS, Mao WJ, Chan CLW, Chen EYH, Conwell Y. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br J Psychiatry. 2015;206(4):283-8. doi:10.1192/bjp.bp.113.139733
17. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. Int J Endocrinol. 2015;2015:615356. doi:10.1155/2015/615356
18. Soewadi E, Pramono D. Determinan terhadap Timbulnya Skizofrenia pada Pasien Rawat Jalan di Rumah Sakit Jiwa Prof. Hb Saanin Padang Sumatera Barat. Berita Kedokteran Masyarakat. 2010;26(2):71-80. doi:10.22146/bkm.3471
19. Teigset CM, Mohn C, Brunborg C, Juuhl-Langseth M, Holmén A, Rund BR. Do clinical characteristics predict the cognitive course in early-onset schizophrenia-spectrum disorders? J Child Psychol Psychiatry. 2018;59(9):1012-23. doi:10.1111/jcpp.12896
20. Golics CJ, Basra MKA, Finlay AY, Salek S. The impact of disease on family members: a critical aspect of medical care. J R Soc Med. 2013;106(10):399-407. doi:10.1177/0141076812472616
21. Miller R. Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I. Curr Neuropharmacol. 2009;7(4):302-14. doi:10.2174/157015909790031229
22. Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem. 2016;16(29):3385-403. doi:10.2174/1568026616666160608084834
23. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci. 2019;42(3):205-20. doi:10.1016/j.tins.2018.12.004
24. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004;53(10):1520-35. doi:10.1136/gut.2003.035568
25. Correll CU, Defraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-36. doi:10.1002/wps.20204
26. Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol. 2006;147(Suppl 1):S82-8. doi:10.1038/sj.bjp.0706428
27. Sprouse-Blum AS, Smith G, Sugai D, Parsa FD. Understanding Endorphins and Their Importance in Pain Management. Hawaii Med J. 2010;69(3):70-1
28. Svensson E, Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Schiöth HB. General Principles of Neuronal Co-transmission: Insights from Multiple Model Systems. Front Neural Circuits. 2019;12:117. doi:10.3389/fncir.2018.00117
29. Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017;6(6):CD009005. doi:10.1002/14651858.cd009005.pub2
30. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, et al. Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology. 2008;199(1):15-27. doi:10.1007/s00213-007-1064-9
31. Sakurai H, Bies RR, Stroup ST, Keefe RSE, Rajji TK, Suzuki T, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013;39(3):564-74. doi:10.1093/schbul/sbr189
32. Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiol Res Pract. 2014;2014:273060. doi:10.1155/2014/273060
Authors
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.
Article Details
